Multiple imaging techniques are commonly used in all phases of cancer management. The early detection of cancer through image-based screening is a major contributor to reduced cancer mortality. Advances in targeted imaging approaches and therapeutic agents require the development of new and improved imaging tools to assess the full spectrum of cancer tumorigenesis. One such emerging imaging modality is MPI for early cancer detection and staging. The Momentum™ MPI system is a translatable imaging technology that offers high contrast, rapid and quantitative 3D imaging capabilities without the need for ionizing radiation or toxic tracers.
Download our whitepaper to learn more about how MPI is accelerating advancements in cancer monitoring and detection.